Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Noelle Cloven et al.|The Lancet Oncology|2019Cited by 533
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine modelsMaria J. Sambade, Carey K. Anders, Amanda E.D. Van Swearingen et al.|Neuro-Oncology Advances|2019Cited by 24